BRAIN Biotech AG


25/05/23 -"2Q22/23 numbers slightly weaker than we have expected but guidance & mid-term targets confirmed and cash at EUR 9.2mn is solid"

Pages
4
Language
English
Published on
25/05/23

EXECUTIVE SUMMARY

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO